Neonatal Respiratory Distress Syndrome Market

Close Monitoring of COVID Positive Neonates in ICUs Reduces Production Stress

The screening of all new infants at high risk of exposure to COVID-19 (coronavirus) is a fast growing phenomenon in healthcare facilities. This is being carried out based on their family history. Companies in the neonatal respiratory disease syndrome market are boosting their production output to meet the demanding needs of clinicians. Manufacturers are educating healthcare professionals to isolate all high-risk neonates in intensive care units (ICUs) to contain the spread of COVID-19 and reduce production stress on pharma companies. As such, the nucleic acid test is being recommended for high-risk neonates.

Neonates are prone to rapidly developing respiratory distress and multiple organ failure. Hence, companies in the neonatal respiratory disease syndrome market are increasing awareness about admitting COVID positive infants in ICUs to enable close monitoring. This is necessary since a second wave of coronavirus is prevalent in the U.S., India, and European countries.

Acute Complications in Infants Inhibit Market Growth

Due to an alarmingly high prevalence of neonatal respiratory disease syndrome worldwide, pharma companies are increasing their production capacities to manufacture antenatal corticosteroids, oxygenation, and ventilation equipment. However, healthcare companies need to address issues of complications after the acute course of respiratory disease syndrome. Acute complications such as air-leak syndromes and pulmonary interstitial emphysema are creating hurdles for companies in the neonatal respiratory disease syndrome market. Companies should increase their focus in laboratory workup and imaging technologies to improve medical outcomes in hospitals and clinics.

The increased coordination among numerous care teams such as respiratory therapists, physicians, and pharmacists is highly recommended to improve clinical numbers. Companies in the neonatal respiratory disease syndrome market are increasing awareness within healthcare commissions for high level of clinical expertise in healthcare settings.

Surfactant Replacement Combined with Mechanical Ventilation Improves Lung Oxygenation

Mechanical ventilation facilitates adequate respiratory support while balancing the risks of oxygen toxicity, barotrauma, and volutrauma. However, this treatment also makes them susceptible to bronchopulmonary dysplasia (BPD) and other chronic lung diseases. Hence, companies in the neonatal respiratory disease syndrome market are increasing the availability of surfactant replacement treatment to improve medical outcomes. Surfactant replacement is gaining popularity as the go-to therapy for reducing the rate of morbidity and mortality, especially in countries with large pockets of poverty.

Companies in the neonatal respiratory disease syndrome market are increasing their R&D activities to determine the best dose, timing, and methods for the delivery of surfactant treatment. This helps to maximize the effects and minimize risks of bronchopulmonary dysplasia in neonates. It has been found that early treatment, with the help of pulmonary surfactant and mechanical ventilation, could remarkably improve lung oxygenation and compliance.

Targeted Treatments and Less Invasive Options Reduce Incidence of BPD in Infants

Apart from surfactant replacement and mechanical ventilation, manufacturers in the neonatal respiratory disease syndrome market are increasing the availability of inhaled nitric oxide treatment. This treatment is becoming a mainstay for neonatal respiratory disease syndrome, owing to its advantage of improving oxygenation and reduce pulmonary inflammation. Treatment measures taken within 12 hrs of birth are being highly recommended by healthcare commissions, since it relieves infants from acute symptoms. The reduction in chronic lung diseases later in life is being achieved in individuals with the help of inhaled nitric oxide treatment.

Targeted treatments and less invasive options for infants are bolstering the credibility credentials of companies in the neonatal respiratory disease syndrome market.These companies are spreading awareness about selective use of surfactants rather than prophylactic use to reduce incidences of bronchopulmonary dysplasia in neonates.

Focus on Nutrition Helps Increase Survival Time of Preterm Neonates

Companies in the neonatal respiratory disease syndrome market are making propositions to administer surfactant differently with the help of catheters. Surfactant treatment is being combined with continuous positive airway pressure (CPAP) to eliminate the need of mechanical ventilation. On the other hand, manufacturers in the neonatal respiratory disease syndrome market are increasing their production capabilities in nebulized surfactant to reduce the need for intubation in preterm infants treated with nasal CPAP. Pharma companies are in discussions with researchers to revise protocols on mechanical oxygenation and ventilation.

The administration of vitamin D in infants is found to stimulate lung maturation. Pharma companies are capitalizing on this opportunity, as vitamin D deficiency leads to fall in oxygen levels and reduces survival time of preterm neonates. As such, vitamin A administration is contributing toward cell growth and decline in BPD rates.